Anzeige
Meldung des Tages: Vor der Neubewertung dank Dealfantasie? Dieser Explorer bringt sich jetzt strategisch in Position

Oncolytics Biotech News

Aktie
WKN:  A2JMW5 ISIN:  CA6823108759 Branche:  Biotechnologie Land:  Kanada
0,9403 $
+0,0854 $
+9,99%
0,8007 € 01.04.26
Depot/Watchlist
Marktkapitalisierung *
62,33 Mio. €
Streubesitz
94,71%
KGV
-3,21
Index-Zuordnung
Nasdaq Composite Index

Oncolytics Biotech News

20.10.25 - PR Newswire
Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada
Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada PR Newswire
29.09.25 - PR Newswire
Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study
Oncolytics Biotech® Announces Update for Potential First-​Line Pancreatic Cancer Registration Study PR Newswire
16.09.25 - PR Newswire
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals PR Newswire
16.09.25 - PR Newswire
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals PR Newswire
16.09.25 - PR Newswire
Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion
Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion PR Newswire
08.09.25 - PR Newswire
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market PR Newswire
08.09.25 - PR Newswire
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market PR Newswire
08.09.25 - PR Newswire
Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions
Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions PR Newswire
02.09.25 - PR Newswire
Breakthrough Cancer Therapies Fuel Regulatory Momentum as Global Market Expands
Breakthrough Cancer Therapies Fuel Regulatory Momentum as Global Market Expands PR Newswire
02.09.25 - PR Newswire
Breakthrough Cancer Therapies Fuel Regulatory Momentum as Global Market Expands
Breakthrough Cancer Therapies Fuel Regulatory Momentum as Global Market Expands PR Newswire
02.09.25 - PR Newswire
Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors
Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors PR Newswire
28.08.25 - PR Newswire
FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone
FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone PR Newswire
28.08.25 - PR Newswire
FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone
FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone PR Newswire
28.08.25 - PR Newswire
Oncolytics Biotech® Announces Upcoming Investor Conferences in September
Oncolytics Biotech® Announces Upcoming Investor Conferences in September PR Newswire
14.08.25 - PR Newswire
Biotech Stocks Rally as Oncology Market Targets $866B by 2034
Biotech Stocks Rally as Oncology Market Targets $866B by 2034 PR Newswire
14.08.25 - PR Newswire
Biotech Stocks Rally as Oncology Market Targets $866B by 2034
Biotech Stocks Rally as Oncology Market Targets $866B by 2034 PR Newswire
14.08.25 - PR Newswire
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment PR Newswire
11.08.25 - PR Newswire
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders PR Newswire
08.08.25 - PR Newswire
Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep
Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep PR Newswire
08.08.25 - PR Newswire
Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange
Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange PR Newswire

Newssuche

Videos

newspaper
20.04.26 -1,87%
Technical Trading: GBP Long im Trend
GBP/USD Long Typ: Open End Turbo WKN: VV7A4S Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »